BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 21668414)

  • 1. A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types.
    Jamieson S; Flanagan JU; Kolekar S; Buchanan C; Kendall JD; Lee WJ; Rewcastle GW; Denny WA; Singh R; Dickson J; Baguley BC; Shepherd PR
    Biochem J; 2011 Aug; 438(1):53-62. PubMed ID: 21668414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling.
    Chaussade C; Rewcastle GW; Kendall JD; Denny WA; Cho K; Grønning LM; Chong ML; Anagnostou SH; Jackson SP; Daniele N; Shepherd PR
    Biochem J; 2007 Jun; 404(3):449-58. PubMed ID: 17362206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI3K pathway dependencies in endometrioid endometrial cancer cell lines.
    Weigelt B; Warne PH; Lambros MB; Reis-Filho JS; Downward J
    Clin Cancer Res; 2013 Jul; 19(13):3533-44. PubMed ID: 23674493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor.
    Berenjeno IM; Guillermet-Guibert J; Pearce W; Gray A; Fleming S; Vanhaesebroeck B
    Biochem J; 2012 Feb; 442(1):151-9. PubMed ID: 22150431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function.
    So L; Yea SS; Oak JS; Lu M; Manmadhan A; Ke QH; Janes MR; Kessler LV; Kucharski JM; Li LS; Martin MB; Ren P; Jessen KA; Liu Y; Rommel C; Fruman DA
    J Biol Chem; 2013 Feb; 288(8):5718-31. PubMed ID: 23275335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition.
    Torbett NE; Luna-Moran A; Knight ZA; Houk A; Moasser M; Weiss W; Shokat KM; Stokoe D
    Biochem J; 2008 Oct; 415(1):97-110. PubMed ID: 18498248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER
    Hosford SR; Dillon LM; Bouley SJ; Rosati R; Yang W; Chen VS; Demidenko E; Morra RP; Miller TW
    Clin Cancer Res; 2017 Jun; 23(11):2795-2805. PubMed ID: 27903677
    [No Abstract]   [Full Text] [Related]  

  • 8. Both p110alpha and p110beta isoforms of phosphatidylinositol 3-OH-kinase are required for insulin signalling in the hypothalamus.
    Tups A; Anderson GM; Rizwan M; Augustine RA; Chaussade C; Shepherd PR; Grattan DR
    J Neuroendocrinol; 2010 Jun; 22(6):534-42. PubMed ID: 20236230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting class IA PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma.
    Höland K; Boller D; Hagel C; Dolski S; Treszl A; Pardo OE; Cwiek P; Salm F; Leni Z; Shepherd PR; Styp-Rekowska B; Djonov V; von Bueren AO; Frei K; Arcaro A
    PLoS One; 2014; 9(4):e94132. PubMed ID: 24718026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition.
    Leroy C; Ramos P; Cornille K; Bonenfant D; Fritsch C; Voshol H; Bentires-Alj M
    Breast Cancer Res; 2016 Apr; 18(1):41. PubMed ID: 27048245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK.
    Tran KB; Kolekar S; Jabed A; Jaynes P; Shih JH; Wang Q; Flanagan JU; Rewcastle GW; Baguley BC; Shepherd PR
    BMC Cancer; 2021 Feb; 21(1):136. PubMed ID: 33549048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse.
    Iyengar S; Clear A; Bödör C; Maharaj L; Lee A; Calaminici M; Matthews J; Iqbal S; Auer R; Gribben J; Joel S
    Blood; 2013 Mar; 121(12):2274-84. PubMed ID: 23341541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages.
    Papakonstanti EA; Zwaenepoel O; Bilancio A; Burns E; Nock GE; Houseman B; Shokat K; Ridley AJ; Vanhaesebroeck B
    J Cell Sci; 2008 Dec; 121(Pt 24):4124-33. PubMed ID: 19033389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ETP-46321, a dual p110α/δ class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis.
    Aragoneses-Fenoll L; Montes-Casado M; Ojeda G; Acosta YY; Herranz J; Martínez S; Blanco-Aparicio C; Criado G; Pastor J; Dianzani U; Portolés P; Rojo JM
    Biochem Pharmacol; 2016 Apr; 106():56-69. PubMed ID: 26883061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI3K p110α/Akt signaling negatively regulates secretion of the intestinal peptide neurotensin through interference of granule transport.
    Li J; Song J; Cassidy MG; Rychahou P; Starr ME; Liu J; Li X; Epperly G; Weiss HL; Townsend CM; Gao T; Evers BM
    Mol Endocrinol; 2012 Aug; 26(8):1380-93. PubMed ID: 22700584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
    Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
    Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.
    Edgar KA; Wallin JJ; Berry M; Lee LB; Prior WW; Sampath D; Friedman LS; Belvin M
    Cancer Res; 2010 Feb; 70(3):1164-72. PubMed ID: 20103642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphoinositide 3-kinases p110α and p110β have differential roles in insulin-like growth factor-1-mediated Akt phosphorylation and platelet priming.
    Blair TA; Moore SF; Williams CM; Poole AW; Vanhaesebroeck B; Hers I
    Arterioscler Thromb Vasc Biol; 2014 Aug; 34(8):1681-8. PubMed ID: 24903091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells.
    Zito CR; Jilaveanu LB; Anagnostou V; Rimm D; Bepler G; Maira SM; Hackl W; Camp R; Kluger HM; Chao HH
    PLoS One; 2012; 7(2):e31331. PubMed ID: 22355357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Class IA Phosphatidylinositol 3-Kinase Isoform p110α Mediates Vascular Remodeling.
    Vantler M; Jesus J; Leppänen O; Scherner M; Berghausen EM; Mustafov L; Chen X; Kramer T; Zierden M; Gerhardt M; Ten Freyhaus H; Blaschke F; Sterner-Kock A; Baldus S; Zhao JJ; Rosenkranz S
    Arterioscler Thromb Vasc Biol; 2015 Jun; 35(6):1434-44. PubMed ID: 25908763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.